Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 12/20 | 0.43 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.37 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5446514 | 0.88 | TDP1 (0.42) | TDP1SLC10A1GPBAR1 | |
| SCHEMBL14399188 | 0.87 | CA9 (0.40) | GPBAR1 | |
| SCHEMBL5443587 | 0.87 | CA9 (0.40) | GPBAR1 | |
| SCHEMBL14400846 | 0.83 | TDP1 (0.56) | TDP1MBOAT4SLC10A1NOS2NFE2L2 | |
| SCHEMBL5444459 | 0.83 | TDP1 (0.56) | TDP1MBOAT4SLC10A1NOS2NFE2L2 | |
| SCHEMBL5451153 | 0.82 | SLC10A1 (0.45) | TDP1SLC10A1GPBAR1 | |
| SCHEMBL5444255 | 0.81 | TDP1 (0.42) | TDP1SLC10A1GPBAR1 | |
| SCHEMBL14374286 | 0.79 | TDP1 (0.41) | TDP1SLC10A1GPBAR1 | |
| SCHEMBL14398788 | 0.76 | GPBAR1 (0.55) | NOS2GPBAR1 | |
| SCHEMBL5445741 | 0.76 | GPBAR1 (0.55) | NOS2GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232577-A1 | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin | ADVANCED LIFE SCIENCES, INC. (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232577-A1 | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin | BET1, PGGT1B, BRCA1 | TDP1 3403/4885MBOAT4 4754/4885SLC10A1 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.